Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
12.532 / 17.032
#100251

Re: Farmas USA

U.S. stock futures higher as investors eye healthcare vote

By Tanya Agrawal

 

(Reuters) - U.S. stock index futures were modestly higher on Thursday as investors turned their attention to President Donald Trump's first significant policy test, as he looks to gets a healthcare bill passed in Congress.

 

Trump and Republican lawmakers pushed on Wednesday for votes for their plan to overhaul Obamacare and said they were making progress in their efforts to win over conservative members of the party who have demanded changes to the legislation.

 

With a vote on the bill possible as soon as Thursday, losing or delaying it would bruise investors' confidence in Trump's ability to deliver on his promises of tax cuts and infrastructure spending.

 

The S&P 500 has gained 10 percent since the election, spurred mainly by Trump's campaign promises to enact legislation that are seen as pro-business, but high valuations of stocks remain a concern.

 

The benchmark index is trading at about 18 times expected forward earnings, compared with a 10-year average of 14, according to Thomson Reuters data.

 

Wall Street ended mixed after a choppy session on Wednesday as investors focused on the fate of the healthcare bill and snapped up stocks after a steep drop the day before.

 

Investors will also keep an eye on a speech by Federal Reserve Chair Janet Yellen for clues regarding the path of future interest rate hikes. Yellen is due to speak at a conference at 8:45 a.m. ET.

 

Minneapolis Fed Chief Neel Kashkari and Dallas Fed President Robert Kaplan are also due to make appearances later in the day.

 

The U.S. central bank raised rates by 25 basis points last week and reiterated that it would raise rates twice more this year, fewer than the three hikes expected by the market.

 

Economic data due on Thursday includes weekly jobless claims at 8: 30 a.m. ET and new home sales number for February at 10 a.m. ET.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#100253

Re: Farmas USA

NVIV

to Initiate Cervical Spinal Cord Injury Study

Health Canada has approved the company’s Investigational Testing Authorization application to commence a clinical study of the Neuro-Spinal Scaffold™ in patients with acute, complete (AIS A) cervical (C5-T1) spinal cord injuries (SCIs).

 

Preparando corto si se deja...

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#100254

Re: Farmas USA

LJPC

3.7M shares at $33.50/share y está en 34,84, +2,4% en pre

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#100255

Re: Farmas USA

XOMA

 

Ayer se me olvidó colgar esto:

 

XOMA Announces Full Repayment of Hercules Technology Growth Capital Debt Obligation

Company extinguishes Hercules term loan; repayment further reduces operating expenses and strengthens XOMA's balance sheet, reflecting its new business strategy

 

it has fully prepaid the outstanding balance of approximately $6.5 million under the Company's term loan with Hercules

 "We have decreased our debt by approximately $16.7 million, or 39 percent, in the past three months. We continue our focus on initiatives that enhance our financial position. Our lean cost structure gives us the opportunity to reach positive cash flow more quickly, creating value for shareholders as we realize multiple revenue streams from our portfolio of programs that are fully funded by partners across the biopharma landscape."

XOMA funded this extinguishment using, in part, proceeds of the approximately $25 million equity offering to Biotechnology Value Fund, L.P., completed in February 2017.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?
  2. Huellas técnicas de largo plazo. ¿Salvará Nvidia al mercado?
  1. Inflación y tipos en el punto de mira, la historia no se repite pero rima
  2. La Euforia Post-Trump: ¿Calma o Tormenta en el Mercado?